Press Releases

Year

February 11, 2019

Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts

-- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients -- -- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by HSS7 in Xolair Naïve CSU patients -- -- 54% (7/13) complete itch response by ISS7 in Xolair Naïve CSU patients -- -- 54%

February 4, 2019

Allakos to Host Investor Day on February 19 in New York City

REDWOOD CITY, Calif. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19 th starting at 12:00 pm ET in New York City

January 29, 2019

Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism

-- 82% (9 of 11) response rate in patients with cholinergic urticaria -- -- 70% (7 of 10) response rate in patients with symptomatic dermographism -- REDWOOD CITY, Calif. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of

January 7, 2019

Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients

-- 12 of 13 (92%) patients achieved a complete response -- -- Results from 3 additional cohorts expected in the first quarter of 2019 -- REDWOOD CITY, Calif. , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and

Pagination

First page
Previous page
Page 1
Current page 2

Displaying 11 - 14 of 14

(Common Stock)

April 12, 2024 11:23 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Toolkit